INSTITUTO DE SALUD CARLOS III

Organisation

Acronym: ISCIII
Role: Partner
Country: ES
Address: St. Sinesio Delgado, 4 (entrance by Ave. Monforte de Lemos, 5).
28029 - Madrid
Website: https://www.isciii.es/Paginas/Inicio.aspx

Programme phases

Funding participation

Joint calls funded by this organisation.

Funded projects

Projects linked to this funding organisation.

INSTITUTO DE SALUD CARLOS III

Organisation

Programme phases

Funding participation

Funded projects

Precision medicine in cholangiocarcinoma: accurate tools for early detection and identification of PRMT5 as a novel pharmacological target

Biomarkers of tumor recurrence in pancreatic cancer

MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases

Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC

Clinical Impact of Intratumor heterogeneity in metastatic breast cancer

Epigenomic regulation of cancer immunity by dietary intervention

Defeating Recurrence and resistance in AML: Multigenomic Approaches to analyse heterogeneity

Dual EPigenetic targeting and Immunotherapy to fight against Cancer

Chronic stress and immunosuppression in lung cancer: focus on epigenetic drivers in cancer-associated fibroblasts

Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer

Sarcoma subtyping and stratification using genome-wide epigenetic profiling

Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT

Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance

Mutated neo-antigens in hepatocellular carcinoma

High resolution project on prognosis and CARE of cancer patients

Charting the epigenomic trajectory of progression towards metastatic colorectal cancer

Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies

Targeting sphingolipid metabolism to improve anti-melanoma immune therapies

Evolution of resistant clones to novel target-directed drugs in colorectal tumors. - A genetic and epigenetic study of intratumoral heterogeneity dynamics

Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer

Understanding and therapeutically exploiting the immunosuppressive paracrine signalling in the tumour microenvironment of metastatic lesions

Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy

Subtype-specific Lung Cancer Organoids based on artificial ECM for Precision Oncology: Closing the Gap Between Preclinical Models and Patient Care

Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma

Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors

Profiling and functional analysis of the Immune environment of eXtramedullary leukemia rELapses

Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin

Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary Cancer

PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine

Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer

Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.

Deciphering Epigenetic Biomarkers to Identify Preleukemic Carriers at Risk

Reverting immune suppression to elicit brain metastasis control

Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences

TArgeting Colon Tumor Initiating Cell heterogeneity

Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response

TargEting the Nectin fAmily to boost Cancer ImmuniTY

Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response

Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumor Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models

TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform

Targeting ROBOs and SLIT guidance cues in the immunosuppressive stromal context of pancreatic cancer (TRanSLIT)

Innovative mRNA vaccine against NSCLC: Designing a platform of targeted polymeric nanoparticles for efficient personalized therapy

Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors.

Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patient

Radiothermal-Driven Immune Activation to Tackle Pancreatic Hypoxic Tumors